Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Zhifei Biological Renews Exclusive China Distribution Pact with Merck for Gardasil 9, Rotateq, and Pneumovax—Shifts to Demand-Driven Supply Model

Fineline Cube Apr 3, 2026
Company Deals Digital

Xellar Biosystems Closes RMB 200M Series A Led by China Life Investment to Build 3D Bio Intelligence Platform

Fineline Cube Apr 3, 2026
Company Deals

Regeneron Partners with TriNetX in $200M Deal to Expand World-Leading Genomic-Phenotypic Data Platform

Fineline Cube Apr 3, 2026
Company Deals

Biocytogen and Sihuan Pharma Forge Strategic Partnership to Accelerate Innovative Drug Development Including Weight Management Therapies

Fineline Cube Apr 2, 2026
Company Deals

Sanli Pharmaceutical Transfers Marketing Rights for 16 Drugs to Hanfang Pharmaceutical in RMB 2 Million Deal

Fineline Cube Apr 2, 2026
Policy / Regulatory

China’s CDE Releases 105th Batch of Reference Preparations for Generic Drug Evaluation, Adds 8 New Drugs

Fineline Cube Apr 2, 2026
Company Drug

Bio-Thera Solutions Gains NMPA Clearance for Phase I/II Trial of PD-1 Biosimilar BAT3306 Combined with Trop2 ADC BAT8008 in Advanced Solid Tumors

Fineline Cube Apr 4, 2026
Company Drug

AstraZeneca’s Imfinzi-Imjudo Combo with Lenvatinib and TACE Shows Significant PFS Benefit in Early-Stage Liver Cancer, EMERALD-3 Trial Reveals

Fineline Cube Apr 3, 2026
Company Drug

Akeso Bio’s AK112 Wins Breakthrough Designation for First-Line NSCLC

Fineline Cube Sep 1, 2022

China’s Akeso Bio has secured a breakthrough therapy designation (BTD) from the Center for Drug...

Company

RemeGen’s H1 2022 Revenue Soars 1,094% on Aidixi, Taiai Sales

Fineline Cube Sep 1, 2022

China-based biotech RemeGen (HKG: 9995) reported RMB 349 million (USD 50.5 million) in revenue for...

Policy / Regulatory

Beijing Adjusts UEBMI Account Management, Boosting Outpatient Coverage

Fineline Cube Aug 31, 2022

The Beijing Municipal Medical Insurance Bureau has adjusted the management of Urban Employee Basic Medical...

Company

Junshi Biosciences’ H1 2022 Financials Show Tuoyi Sales Growth Despite Revenue Drop

Fineline Cube Aug 31, 2022

Shanghai-based Junshi Biosciences (HKG: 1877) reported a 55.26% year-on-year (YOY) revenue decline to RMB 946.05...

Company Drug

Connect Biopharma Completes Phase I Trial of CBP-174 for Itch in Skin Diseases

Fineline Cube Aug 31, 2022

Sino-US biotech Connect Biopharma Holdings Ltd (NASDAQ: CNTB), headquartered in San Diego, California, and Taicang,...

Company Deals

RoosterBio Taps MBL Beijing Biotech as Exclusive Distributor in China

Fineline Cube Aug 31, 2022

US-based RoosterBio Inc. has appointed MBL Beijing Biotech, a subsidiary of JSR Life Sciences Company,...

Company Drug

Boehringer, Eli Lilly’s Jardiance Wins NMPA Approval for Heart Failure with Preserved Ejection Fraction

Fineline Cube Aug 31, 2022

Boehringer Ingelheim and Eli Lilly (NYSE: LLY) announced that China’s National Medical Products Administration (NMPA)...

Company Deals

E-nitiate Biopharma Raises RMB 100M in Series A to Advance Autoimmune Disease Drugs

Fineline Cube Aug 31, 2022

China-based E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd, a drug developer focused on autoimmune diseases, has raised...

Company Deals

Kangtai Bio Partners with Philippine Firm on Pneumonia Vaccines

Fineline Cube Aug 31, 2022

Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has partnered with an unnamed Philippine enterprise...

Company

MicroPort Scientific Posts 10% Revenue Growth Despite COVID-19 in 2022 Interim Results

Fineline Cube Aug 31, 2022

China-based MicroPort Scientific Corp. (HKG: 0853) reported unaudited 2022 interim results ending June 30, 2022,...

Company Drug

Merck’s Gardasil 9-Valent HPV Vaccine Approved for Expanded Age Range in China

Fineline Cube Aug 31, 2022

US-based Merck Sharp & Dohme (MSD; NYSE: MRK) announced that China’s National Medical Products Administration...

Company Deals

Onekdrug Raises Series B+ Funding to Boost Pharmaceutical B2B Services

Fineline Cube Aug 31, 2022

Hunan Wholesale Pharmaceutical Technology Co., Ltd, operating as Onekdrug, has raised tens of millions of...

Company Drug

Sinocelltech’s Ripertamab Wins NMPA Approval for DLBCL Treatment

Fineline Cube Aug 31, 2022

China-based Sinocelltech Group Ltd (SHA: 688520) has received New Drug Application (NDA) approval from the...

Company

Fosun Pharma’s H1 2022 Revenue Rises 25.9% on New Drug Launches, Global Expansion

Fineline Cube Aug 30, 2022

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) reported RMB 21.34 billion (USD 3 billion)...

Company Drug

Clover Biopharma’s SCB-2019 Vaccine Shows Strong Immune Response to Omicron BA.5

Fineline Cube Aug 30, 2022

China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) announced positive Phase II/III trial results for its COVID-19...

Company Drug

Staidson and J&J’s Teclistamab Gain Breakthrough Designation for Hemophilia and Myeloma

Fineline Cube Aug 30, 2022

The Center for Drug Evaluation (CDE) has indicated that Staidson (Beijing) Pharmaceutical Co., Ltd’s (SHE:...

Company Deals

Fosun Pharma to Invest RMB 1B in Chengdu Vaccine Base

Fineline Cube Aug 30, 2022

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) announced that its subsidiaries, Shanghai Fosun Pharmaceutical...

Company Drug

InnoCare Pharma and CStone Pharmaceuticals’ Drugs Receive Prioritized CDE Review

Fineline Cube Aug 30, 2022

The Center for Drug Evaluation (CDE) has granted prioritized review status to InnoCare Pharma’s (HKG:...

Company Deals Digital

Luca Healthcare Raises Pre-Series A Funding for Digital Biomarker R&D

Fineline Cube Aug 30, 2022

Shanghai-based Luca Healthcare Co., Ltd, a firm specializing in digital biomarkers and therapeutics, has raised...

Company Drug

Biocytogen and Tracon Pharmaceuticals Gain FDA IND Approval for Sarcoma Trial

Fineline Cube Aug 30, 2022

China-based Biocytogen (Beijing) Co., Ltd and US-based Tracon Pharmaceuticals Inc. (Nasdaq: TCON) announced that the...

Posts pagination

1 … 610 611 612 … 646

Recent updates

  • Staidson Pharma Announces $182M Private Placement to Advance Innovative Biologics Pipeline
  • Bio-Thera Solutions Gains NMPA Clearance for Phase I/II Trial of PD-1 Biosimilar BAT3306 Combined with Trop2 ADC BAT8008 in Advanced Solid Tumors
  • Zhifei Biological Renews Exclusive China Distribution Pact with Merck for Gardasil 9, Rotateq, and Pneumovax—Shifts to Demand-Driven Supply Model
  • Xellar Biosystems Closes RMB 200M Series A Led by China Life Investment to Build 3D Bio Intelligence Platform
  • Regeneron Partners with TriNetX in $200M Deal to Expand World-Leading Genomic-Phenotypic Data Platform
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Staidson Pharma Announces $182M Private Placement to Advance Innovative Biologics Pipeline

Company Drug

Bio-Thera Solutions Gains NMPA Clearance for Phase I/II Trial of PD-1 Biosimilar BAT3306 Combined with Trop2 ADC BAT8008 in Advanced Solid Tumors

Company Deals

Zhifei Biological Renews Exclusive China Distribution Pact with Merck for Gardasil 9, Rotateq, and Pneumovax—Shifts to Demand-Driven Supply Model

Company Deals Digital

Xellar Biosystems Closes RMB 200M Series A Led by China Life Investment to Build 3D Bio Intelligence Platform

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.